Related Experiment Video
Updated: May 3, 2026
Isolation and Characterization of Neutrophils with Anti-Tumor Properties
Published on: June 19, 2015
CBP/P300 BRD Inhibition Reduces Neutrophil Accumulation and Activates Antitumor Immunity in TNBC
Xueying Yuan1, Xiaoxin Hao2, Hilda L Chan2
1Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX, USA.
A novel drug targeting CREB binding protein (CBP)/P300 bromodomain (BRD) reduces tumor-promoting neutrophils in triple-negative breast cancer (TNBC). This inhibition also enhances anti-tumor immunity and improves treatment response.
Area of Science:
- Oncology
- Immunology
- Molecular Biology
Background:
- Tumor-associated neutrophils (TANs) promote immunosuppression and progression in triple-negative breast cancer (TNBC), correlating with poor prognosis.
- Dysregulation of CREB binding protein (CBP)/P300, particularly its bromodomain (BRD), is implicated in various cancers.
Conclusions:
- Targeting the CBP/P300 BRD with IACS-70654 represents a promising strategy for managing neutrophil-enriched TNBC.
- This approach modulates the tumor microenvironment by reducing TANs and enhancing anti-tumor immunity.
- Combining CBP/P300 BRD inhibitors with standard therapies warrants investigation in future clinical trials for TNBC.
More Related Videos
08:17A Human Peripheral Blood Mononuclear Cell PBMC Engrafted Humanized Xenograft Model for Translational Immuno-oncology I-O Research
Published on: August 15, 2019
08:19Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo
Published on: July 20, 2019
